Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solosec in bacterial vaginosis
NCT02418845Phase 3Completed
- Sponsor
- Symbiomix Therapeutics
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of secnidazole in bacterial vaginosis (BV), sponsored by Symbiomix Therapeutics. Started May 2015; status: completed.
02
Drugs
secnidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT02418845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418845.